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To evaluate whether circulating soluble (s) apoptosis-related proteins and
inflammation markers are increased in long-term disease free breast cancer
survivors and associated with cardiotoxicity, and if subgroups could be identified
based on the applied treatments.
Patients and methods
Circulating tumor necrosis factor (TNF) α, sTNF-receptor (sTNF-R) 1 and 2, sFas,
sFas ligand, sTNF-related apoptosis inducing ligand (sTRAIL) and serum HER2
were measured with immunoassay (ELISA) in long-term disease-free breast cancer
survivors after adjuvant anthracyclines and chest wall irradiation. High-sensitivity
C-reactive protein (HS-CRP), fibrinogen, plasma B-type and N-terminal atrial
natriuretic peptide (NT-ANP and BNP) were also determined. Serum platinum was
analyzed in subjects who had received carboplatin.
Results
34 patients with a median follow-up of 6.0 years, and 12 healthy age-matched
women were enrolled. Chemotherapy, consisting of standard-dose (5x fluorouracil,
epirubicin (450 mg/m2), cyclophosphamide (FEC), n=14) or high-dose (4x FEC,
epirubicin (360 mg/m2), and myeloablation with 1600 mg/m2 carboplatin, 6 g/m2
cyclophosphamide, thiotepa 480 mg/m2, n=20) with hematopoietic stem cell
rescue, preceded irradiation and tamoxifen. Although no associations with
natriuretic peptides or clinical cardiotoxicity (n=2) were observed, circulating
apoptosis markers were higher in breast cancer survivors than in controls. SFas
ligand and sTRAIL were higher in the high-dose than in the standard-dose group.
Circulating platinum levels did not correlate with apoptosis marker levels.
Conclusions
Circulating apoptosis marker levels were increased in long-term disease-free breast
cancer survivors, treated with adjuvant chemoradiotherapy, and were higher after
myeloablative than after standard-dose chemotherapy. The potential relation with
late cardiotoxicity of antineoplastic therapy deserves further study.
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shed into the circulation and can be quantified in serum with an immunosorbent
assay.19
The neurohormones B-type natriuretic peptide (BNP) and N-terminal atrial
natriuretic peptide (NT-ANP) are elevated in patients with low LVEF values and
clinical heart failure, and increase with the NYHA class.20-22 Furthermore,
increased natriuretic peptide levels have been related to decreased left ventricular
ejection fraction (LVEF) values in patients with left ventricular dysfunction or
coronary artery disease.23,24 As a consequence, elevated natriuretic peptide values
are considered to be indicative of left ventricular dysfunction. In patients who
received adjuvant anthracycline-based chemotherapy followed by chest wall
irradiation and oral tamoxifen maintenance treatment for early stage breast cancer,
we previously observed that plasma natriuretic peptides increased during the first
year after the start of treatment.25
To date, no data is available regarding circulating levels of TNF-related soluble
apoptotic proteins, acute phase proteins and serum HER2 in relation to the
occurrence of late cardiotoxicity, during follow-up of breast cancer survivors who
received potentially cardiotoxic treatment. Therefore, in this cross-sectional study,
we determined whether circulating levels of sTNF-related apoptotic proteins,
HER2 and acute phase proteins are increased and associated with cardiac
dysfunction, in long-term disease-free breast cancer survivors after adjuvant
anthracycline chemotherapy and chest wall irradiation. Additionally, we evaluated
whether subgroups could be identified, based on the applied treatment regimens.
PATIENTS AND METHODS
Breast cancer survivors and treatment
Between February 2003 and June 2004, breast cancer patients visiting the oncology
outpatient clinic of the University Medical Center Groningen, The Netherlands for
routine follow-up, were asked to participate in this study. Eligible patients were
those who were treated successfully in a nation wide randomized trial comparing
efficacy of two adjuvant anthracycline-containing chemotherapy regimens.26 In this
randomized study, patients aged 18-55 years received either 5 three-weekly cycles
of standard dose 5-fluorouracil (5-FU) (500 mg/m2), epirubicin (90 mg/m2) and
cyclophosphamide (500 mg/m2) (FEC) or 4 courses of FEC followed by high-dose
cyclophosphamide (1500 mg/m2), thiotepa (120 mg/m2) and carboplatin (400
mg/m2), daily for 4 days (4x FEC+CTC). Hematopoietic stem cells were reinfused
7 days after the start of high-dose CTC. In both treatment arms, chemotherapy was
followed by locoregional irradiation, which was started after hematological
recovery from the last chemotherapy cycle. The dose applied to the supraclavicular
and axillary lymph node area was between 46 and 50 Gy in 23-25 fractions. Chest
wall irradiation was performed in 20-25 fraction to a dose of 40 to 50 Gy. In the
case of breast conserving surgery, an additional boost of 16 to 20 Gy was
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INTRODUCTION
The use of chemotherapy in the treatment of early breast cancer has lead to
improved prognosis and survival. As a result, long-term complications related to
chemotherapeutic agents become more and more of an issue in clinical practice.
Several antineoplastic agents, anthracyclines in particular, are known to have
adverse effects on the cardiovascular system (for review see 1. Anthracycline-
induced cardiotoxicity mostly consists of cumulative dose-dependent
cardiomyopathic alterations that can ultimately lead to heart failure. Besides
anthracyclines, other antineoplastic agents can also induce cardiotoxicity. For
instance, acute symptomatic cardiotoxicity occurs in 5-28% of the patients treated
with high-dose cyclophosphamide.2-4
Currently, left ventricular ejection fraction (LVEF) measurement is generally
accepted as the diagnostic tool for the detection of anthracycline-related
cardiotoxicity. However, with this technique only functional loss can be detected.
When a drop in LVEF occurs, the myocardial damage has already occurred.
Therefore, many investigators have searched for alternative methods for earlier
detection or prediction of chemotherapy-induced cardiac injury, to enable medical
intervention that limits myocardial injury and symptomatic cardiac dysfunction.
In patients with heart failure unrelated to anticancer treatment, cardiomyocyte
apoptosis is increased.5,6 Plasma levels of the soluble forms of several members
belonging to the tumor necrosis factor (TNF)-superfamily of apoptosis-related
proteins (TNFα, TNF receptor (TNF-R) 1 and 2, Fas and Fas ligand) are increased
in heart failure and correlate positively with New York Heart Association (NYHA)
functional class.7-10 Increased TNF-related apoptosis-inducing ligand (TRAIL)
cDNA expression is present in peripheral blood mononuclear cells of heart failure
patients.11
Next to plasma markers of apoptosis, serum levels of the acute phase reactants
high-sensitivity C-reactive protein (HS-CRP) and fibrinogen are elevated in heart
failure patients and positively associated with the NYHA class. Both HS-CRP and
fibrinogen are independent negative prognostic factors in these patients.12,13
Increased plasma fibrinogen may also be suggestive of a hypercoagulable state in
heart failure.14
The human epidermal growth factor receptor 2 (HER2; also known as erbB-2) is
predominantly known for its role in breast cancer, in which it is
overexpressed/amplified in 25-30% of patients and related to worse prognosis.15
The anti-HER2 antibody trastuzumab is associated with an increased risk of cardiac
dysfunction, especially if administered with concurrent anthracycline treatment.16
HER2 is hypothesized to play a role in the pathogenesis of heart failure,
predominantly based on the observation that mice lacking the intracardiac gene
coding for HER2 develop severe dilated cardiomyopathy shortly after birth.17,18
The proteolytically cleaved extracellular domain of the transmembrane HER2 is
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administered to the tumor bed. Tamoxifen (40 mg/day orally) was started in both
treatment arms after bone marrow recovery for 2-5 years.
To be eligible for the current study, patients were required to be free of disease,
with the last course of anthracycline-containing chemotherapy at least 6 months
prior to inclusion.
A history and physical examination with special attention to signs and symptoms
related to heart failure was performed. If present, the severity of heart failure was
classified according to the NYHA functional scale.
Age-matched, healthy female individuals, with no history of malignancy or
cardiovascular disease, recruited through an advertisement, served as controls.
The study protocol was approved by the local ethics committee. Written informed
consent was obtained from all participants.
Blood sampling
Peripheral blood samples were drawn and transferred in 10 mL disposable tubes
containing either 2-natrium-ethylenediamine tetra-acetic acid (EDTA), heparin or
no additive for serum collection. After sampling, tubes containing EDTA or
heparin as an additive were placed on ice immediately. In tubes containing no
additive, blood was allowed to clot at room temperature until centrifugation. Serum
and plasma were separated by centrifugation at 4ºC, and stored at –80ºC until
determination.
Soluble apoptosis-related proteins
Plasma levels of TNFα, sTNF-R1, sTNF-R2, sFas, sFas ligand and sTRAIL were
determined using commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Quantikine; R&D systems, Minneapolis, MN, USA) following the
manufacturer’s instructions. Serum HER2 was determined with a sandwich ELISA
(HER-2/ECD assay; Oncogene Sciences, Cambridge, MA, USA). TNFα was
measured in EDTA plasma, sTNF-R1 and sTNF-R2 in heparin plasma. Serum was
used for sFas, sFas ligand, sTRAIL and HER2.
Neurohormones
BNP and NT-ANP were analyzed as markers for cardiac dysfunction. BNP plasma
levels were measured with an immunoradiometric assay (Shionora, Osaka, Japan),
with a normal range of 1-10 pmol/L. NT-ANP levels were assessed with a
radioimmunoassay (Biotop, Oulu, Finland), with a normal range between 150 and
500 pmol/L.
Acute phase reactants
Serum HS-CRP and fibrinogen were determined as markers for inflammation. HS-
CRP was assayed with the BNII Nephelometer (Dade Behring, Brussels, Belgium).
Lower detection limit 0.16 mg/L (normal values 0.16-10 mg/L). Plasma fibrinogen
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was measured with the Clauss functional assay on an STA coagulation analyzer
(normal range 1.7-3.5 g/L).
Platinum
Serum platinum concentrations were analyzed in the patients who had received
carboplatin-based chemotherapy (4x FEC+CTC). This analysis was performed
using a highly sensitive procedure in which high-pressure decomposition of plasma
is followed by adsorptive voltammetric determination of platinum with a detection
limit of 6 pg/g.27
HER2 tumor status
Formalin-fixed, paraffin-embedded tumor samples were stained with antibodies
against HER2 28. Staining for HER2/neu was scored as follows: a score of 0, no
staining; a score of 1, more than 10 percent of cells were weakly positive; a score of
2, moderate homogeneous staining; and a score of 3, strong homogeneous staining.
A score of 0-1 was considered as HER2 negative and a score of 2-3 was considered
HER2 positive.
Statistics
Quantitative variables were compared between two groups using an unpaired t test
for normally distributed variables or a Mann-Whitney-U test for skewed distributed
variables. Normally distributed variables are reported as mean ±SD, skewed
distributed variables are reported as median and range. Correlations between
variables were calculated using Pearson’s correlation coefficient or Spearman rank
sum test. All P values were two-sided and P<0.05 was considered statistically
significant.
RESULTS
Thirty-four breast cancer survivors, with a median age of 52 years and a median
follow-up duration of 6.0 years since the start of chemotherapy, were enrolled.
None of the patients had evidence of cardiac disease at the start of breast cancer
treatment. 5x FEC had been the applied chemotherapy regimen in 14 (41%)
patients, 20 (59%) had received 4x FEC+CTC. All breast cancer survivors had
received locoregional irradiation to the chest wall and axillary lymph nodes with a
median dose of 50 (range 32-50) Gy and oral tamoxifen maintenance therapy; 27
for the duration of 2 years and 7 for the duration of 5 years. Sixteen patients had
received left sided chest wall irradiation and right sided chest wall irradiation had
been performed in the remaining 18 patients.
Second primary breast cancers were diagnosed in three breast cancer survivors
during follow-up after adjuvant treatment; one after 5x FEC and two after 4x
FEC+CTC. All three underwent surgery followed by adjuvant chemotherapy (6x
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CMF; cyclophosphamide, methotrexate and 5-fluorouracil), one patient underwent
chest wall irradiation. At the time of enrollment in the current study, the patients
were free of malignant disease. For the analysis of the influence of the applied
antineoplastic treatment on circulating soluble apoptosis marker levels the three
patients with a second breast cancer were excluded.
The control group consisted of 12 healthy women with a median age of 51 (35-63)
years.
Cardiac evaluation
Symptoms of heart failure (NYHA II) were present in two breast cancer survivors
(6%), both after 4x FEC+CTC. Plasma natriuretic peptide values median 6.0 years
after treatment, did not differ between breast cancer survivors and controls. Plasma
BNP >10 pmol/L was found in eight of 34 breast cancer survivors, but in none of
the controls. In one of these eight patients, elevated plasma BNP coincided with
symptoms of heart failure. Plasma NT-ANP values above the upper limit of normal
were not observed in the control group, whereas two breast cancer survivors, both
without heart failure symptoms, had plasma NT-ANP levels above normal values.
Circulating proteins
Circulating soluble apoptosis-related proteins Figure 1 and table 1 represent
circulating plasma apoptosis marker concentrations in breast cancer survivors
compared to controls. Median plasma TNFα, serum sFas, sFas ligand and sTRAIL
levels were higher in breast cancer survivors than in controls (Table 1). A trend was
observed for higher sTNF-R2 values in patients. Plasma sTNF-R1 levels did not
differ between patients and controls. SFas correlated with sFas ligand (R = 0.497, P
< 0.001), sTNF-R2 (R = 0.648, P < 0.001) and sTRAIL (R = 0.555, P < 0.001).
STNF-R2 correlated with sTNF-R1 (R = 0.444, P < 0.001), sFas ligand (R = 0.448,
P = 0.002) and sTRAIL (R = 0.568, P < 0.001). Furthermore, sTRAIL correlated
with sFas ligand (R = 0.440, P = 0.002) No correlations were observed between
follow-up duration and plasma apoptosis marker concentrations. No subgroups
could be identified based on high serum and plasma levels (> mean +1 or 2SD) of
more than one of the circulating apoptosis markers.
Serum HER2 Serum HER2 was higher in breast cancer survivors than controls. For
30 of the 34 patients, primary tumor HER2 status had been determined; eight
patients had a HER2-positive primary tumor, whereas the remaining 22 had HER2-
negative primary tumors. Serum HER2 did not differ between patients with a
primary HER2-positive tumor and those with HER2-negative tumors. Furthermore,
patients with HER2-negative primary tumors had higher serum HER2 levels than
controls (P = 0.035), as well as patients with a HER2-positive primary tumor (P =
0.004) (data not shown).
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Figure 1. Dot plots of circulating soluble apoptosis-related proteins of the TNF-superfamily and HER2 in
breast cancer survivors and healthy age-matched controls. Lines represent median values for TNFα and
mean for sTNF-R1, sTNF-R2, sFas, sFas ligand, sTRAIL and HER2. (A) TNFα (pg/mL), (B) sTNF-R1
(ng/mL), (C). sTNF-R2 (ng/mL), (D) sFas (ng/mL), (E) sFas ligand (pg/mL), (F) sTRAIL (pg/mL), (G)
HER2 ECD (pg/mL).
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Acute phase reactants Serum HS-CRP and plasma fibrinogen levels did not differ
between breast cancer survivors and controls. HS-CRP and fibrinogen were
positively associated (R = 0.385, P = 0.008). HS-CRP correlated positively with
sTNF-R2 (R = 0.520, P < 0.001). In breast cancer survivors with high HS-CRP
and/or fibrinogen (> mean +1 or +2 SD), TNF-related apoptotic protein
concentrations were not different from subjects with low HS-CRP and/or
fibrinogen (< mean + 1 or 2SD).






TNFα (pg/mL) 0.6 (0.3-3.3) 1.4 (0.5-15.7) 0.028
sTNF-R1 (ng/mL) 0.9 (0.7-1.3) 0.8 (0.5-1.6) 0.587
sTNF-R2 (ng/mL) 1.9 (±0.4) 2.3 (±0.7) 0.051
sFas (ng/mL) 8.0 (6.5-11.8) 10.1 (6.4-16.2) 0.009
sFas ligand (pg/mL) 64 (±22) 80 (±20) 0.029
STRAIL (pg/mL) 71 (±28) 97 (±37) 0.029
HER2 ECD (ng/mL) 9.4 (±1.7) 11.1 (±1.8) 0.005
HS-CRP (mg/L) 1.0 (0.2-4.8) 1.6 (0.2-6.8) 0.341
Fibrinogen (g/L) 3.0 (±0.5) 3.3 (±0.5) 0.119
BNP (pmol/L) 4.0 (1.0-9.5) 5.6 (0.8-25.5) 0.476
BNP >10 pmol/L - 8
NT-ANP (pmol/L) 255 (118-426) 273 (121-557) 0.532
NT-ANP >500 pmol/L - 2
Data are expressed as median (range) or mean (±SD)
Serum and plasma markers in relation to cardiac dysfunction
In breast cancer survivors with plasma NT-ANP and/or BNP values above normal
values, circulating apoptosis marker, HER2, nor acute phase protein levels were
different from subjects with plasma natriuretic peptide concentrations within
normal ranges. No correlations were observed between plasma soluble apoptosis
markers and natriuretic peptides. HS-CRP and fibrinogen plasma levels did not
correlate with plasma BNP or NT-ANP.
Serum and plasma markers in relation to treatment
We evaluated whether subgroups could be identified based on the applied
chemotherapy regimens with regard to the circulating levels of the soluble proteins.
For this analysis, the three breast cancer survivors with a second primary tumor
were excluded. In the remaining 31 patients, subjects who had received high-dose
CTC followed by hematopoietic stem cell reinfusion had markedly higher serum
sFas ligand and sTRAIL levels than women treated with standard-dose
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chemotherapy (Table 2). A trend for higher sFas levels was observed in patients
who had received high-dose chemotherapy. Acute phase reactants HS-CRP and
fibrinogen were not different in women who had received high-dose chemotherapy,
compared to patients after standard-dose chemotherapy.
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Radiation therapy No differences were detected between patients who had received
left versus right-sided chest wall irradiation, with regard to the circulating
apoptosis-related proteins, serum HER2 or acute phase proteins. In addition,
natriuretic peptide values did not differ between subjects after left sided compared
to women after right-sided chest wall irradiation.
Tamoxifen Serum and plasma apoptosis marker, serum HER2 and acute phase
protein levels were not different in the patients who had received 2 years tamoxifen
compared to patients who had received tamoxifen for 5 years. In addition, the
duration of tamoxifen use did not correlate with levels of the measured circulating
proteins.
Platinum In the subgroup of 18 women who had received chemotherapy containing
carboplatin (4x FEC+CTC), we evaluated if persisting circulating platinum could
explain the higher circulating plasma soluble apoptosis markers. Circulating
platinum concentrations ranged from 17 to 223 pg/g, with a median of 64 pg/g
plasma at a median follow-up of 6.5 (range 4.1-9.8) years. Serum platinum levels
decreased with longer follow-up duration (Figure 2). Partial Spearman correlation
coefficients, with adjustment for follow-up duration, revealed no associations
between circulating platinum concentrations and any of the serum and plasma
apoptosis markers.
DISCUSSION
In this cross-sectional study, we observed for the first time that circulating levels of
the apoptosis-related proteins TNFα, sFas, sFas ligand, sTRAIL and HER2 were
higher in disease-free breast cancer survivors, at a median follow-up of 6 years
after anticancer treatment, than in age-matched healthy controls. No association
was observed between the increased circulating apoptosis marker levels and cardiac
dysfunction, based on the existence of symptomatic heart failure, which was
observed in two breast cancer survivors, or elevated plasma BNP and NT-ANP.
Remarkably however, after a median follow-up of more than 6 years, sFas ligand
and sTRAIL were higher in the breast cancer survivors who had received high-dose



















g) Figure 2.Dot plot of serum platinum concentrations
(pg/g) in relation to the time since the start of
chemotherapy in months after the start of 4x
FEC+CTC treatment (n=18). Line, R and P
value represent Pearson correlation coefficient.
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chemotherapy, followed by hematopoietic stem cell rescue, compared to breast
cancer survivors after standard-dose chemotherapy.
Plasma BNP was elevated in eight of the breast cancer survivors, with symptomatic
heart failure being present in one of these patients. NT-ANP was elevated in two
patients, both without heart failure symptoms. Since, natriuretic factors can become
elevated before the development of cardiac functional loss,29 patients with an
asymptomatic elevation of plasma natriuretic peptides after anticancer treatment
may be at increased risk for developing cardiac dysfunction and may require more
intensive cardiac follow-up.
Although no direct association with cardiac dysfunction was observed in our breast
cancer survivors after potentially cardiotoxic treatment, the increase in plasma
soluble apoptotic protein levels might be indicative of subtle ongoing cardiac
damage and as such, may be associated with the development of cardiac
dysfunction later on. Recently, a population-based study showed that in women
who participated in a large prospective cohort study and were free of
cardiovascular disease, increased baseline sTNF-R1, sTNF-R2 and CRP plasma
levels were found to be related to a higher risk of developing cardiovascular disease
during follow-up.30
Atherosclerosis is considered to be an inflammatory process and increased serum
HS-CRP levels are present in patients with heart failure based on coronary artery
disease and non-ischemic causes.31-33 In addition, elevated serum fibrinogen levels
were shown in heart failure patients, and were associated with higher NYHA
class.34 We previously reported that serum HS-CRP and plasma fibrinogen were
higher in cured testicular cancer patients at a median follow-up of 7 years since the
start of cisplatin-based chemotherapy, than in controls.35 In our breast cancer
survivor population however, serum HS-CRP and plasma fibrinogen concentrations
were not different from controls. Furthermore, we observed no associations
between the acute phase reactants and plasma natriuretic peptides or apoptotic
proteins.
To our knowledge, the results presented in this report provide the first evidence of
increased circulating apoptosis-related protein levels during long-term follow-up
after antineoplastic therapy for breast cancer, especially after high-dose
chemotherapy and hematopoietic stem cell rescue.
A possible explanation for the increased plasma apoptosis marker concentrations
long after high-dose chemotherapy may be the prolonged retention of circulating
platinum in the body after carboplatin-containing chemotherapy. Retention of
circulating platinum was observed in 61 testicular cancer patients and 21 patients
with an ovarian malignancy cured with cisplatin-based chemotherapy. It was
suggested that persisting circulating platinum is associated with long-term sequelae
of chemotherapy.36,37 In the testicular cancer patients, the mean plasma platinum
concentration was 65 pg/g, after a median follow-up of 14 years following
platinum-containing chemotherapy with cisplatin doses ranging from 350-950
mg/m2.38 In the current study, we observed a median serum platinum concentration
CIRCULATING APOPTOSIS-RELATED PARAMETERS IN LONG-TERM DISEASE-FREE BREAST CANCER SURVIVORS
121
of 64 pg/g, at a median of 6.5 years after carboplatin-based chemotherapy at a dose
of 1600 mg/m2. We found no associations between circulating serum platinum
concentrations and serum and plasma TNF-related apoptotic protein levels. This
suggests that the platinum concentration per se is at least not the only risk factor for
late toxicity.
Prior tamoxifen treatment may also have influenced circulating apoptosis marker
levels. To date, no data are available with regard to the in vivo effects of tamoxifen
on plasma circulating apoptosis marker levels. Only limited evidence, derived from
in vitro studies in breast cancer cells, indicate that the effects of tamoxifen on Fas
ligand membrane expression may depend on the tamoxifen dose.39,40 All patients in
the current study had received tamoxifen for the duration of two or more years.
Although the duration of tamoxifen use was not associated with circulating levels
of the soluble apoptosis markers, the effects of tamoxifen treatment on soluble
apoptosis markers remains cannot be excluded based on these results.
Next to tamoxifen, radiation therapy to the chest wall may also have played a role
in the increased circulating apoptosis marker concentrations in our study
population. In patients treated with total body irradiation prior to bone marrow
transplantation for hematological malignancies, plasma TNFα concentrations were
increased at 4 hours after irradiation, compared to pre-treatment levels.41 To our
knowledge however, no data exist regarding plasma levels of circulating apoptosis
markers in patients with long-term follow-up after radiotherapy to the chest wall.
Since all patients in the current study underwent chest wall irradiation, the
influence of radiotherapy on the plasma soluble apoptosis marker levels could not
be determined.
Serum HER2 levels were higher in our population of breast cancer survivors in
comparison to control subjects, but was not associated with cardiac dysfunction or
treatment regimen. In patients with HER2-positive active breast cancer, serum
levels of HER2 are increased and correlate positively with the number of metastatic
sites.42 In our study, the HER2 status of the primary tumor did not explain the
higher serum HER2 levels in the breast cancer survivors. The higher serum HER2
concentrations may be related to an altered basal apoptotic state. Several studies
have linked HER2 to protection from apoptosis. In ovarian cancer cells for
instance, endogenous HER2 overexpression is associated with resistance to TNF-
induced cytotoxicity.43 The increased soluble apoptosis marker and HER2 levels,
observed in the current study, could suggest an interaction between HER2 shedding
and cleavage of ligands and receptors involved in the death receptor apoptotic
pathways.
Considerations for interpreting the results
Our breast cancer survivor population had received a relatively low cumulative
epirubicin dose of either 450 mg/m2 in the standard-dose arm (5x FEC) or 360
mg/m2 in the high-dose arm (4x FEC+CTC). Both the standard-dose and the high-
dose regimen contained cyclophosphamide, 2.5 g/m2 and 8.0 g/m2 respectively,
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which has also been related to cardiotoxicity.44,45 Mild clinical cardiac dysfunction
was observed in only two breast cancer survivors after moderate dose
chemotherapy and chest wall irradiation. The limited number of breast cancer
survivors who experienced (mild) symptomatic heart failure at the time of
evaluation, could explain for the fact that we did not observe a relation between the
circulating apoptosis marker levels and cardiac dysfunction in our study population.
The small sample size of this cross-sectional study may also have limited the
statistical significance of the findings. In addition, because multiple circulating
apoptosis-related proteins were investigated, multiple testing had to be performed
while analyzing our data, which could theoretically have increased the type I (α)
error.
The cytokines TNFα and sTRAIL are known to have pro-apoptotic effects,46,47
whereas the soluble forms of both death-receptors (Fas and TNF-R2) are linked to
inhibition of apoptosis, by binding their specific ligands after which the pro-
apoptotic signal is lost.48,49 It is remarkable that we observed higher plasma levels
of both pro- and anti-apoptotic proteins in breast cancer survivors compared to
controls. An explanation for the elevated plasma levels of sFas and sTNF-R2 may
be the proteolytic cleavage and subsequent release in the circulation of increased
membrane-expressed receptor.
The pathogenetic role of the increase in both pro- and anti-apoptotic circulating
proteins in this population of breast cancer survivors remains to be determined. The
improved diagnostic and therapeutic modalities in recent years, make the early
detection and prediction of late sequelae caused by anticancer therapy of increasing
interest. Increased serum pro-inflammatory cytokine (TNF-R2 and interleukin-1)
levels were found to be associated with fatigue, in 40 breast cancer survivors at 5
years after diagnosis.50 Whether the higher levels of circulating soluble apoptosis
markers in breast cancer survivors compared to controls are associated with long-
term sequelae deserves further study.
In summary, we observed that long-term breast cancer survivors treated with
anthracyclines and irradiation had higher circulating levels of TNFα, sFas, sFas
ligand, sTRAIL and sHER2 than healthy age-matched women, especially when
they received high-dose chemotherapy followed by hematopoietic stem cell rescue.
In this small cross-sectional study, no clear associations were observed between
circulating apoptosis markers and the existence of cardiac dysfunction, measured
with natriuretic peptides. It remains to be determined whether the higher circulating
soluble apoptosis markers play a pathogenetic role in the long-term sequelae of
anticancer therapy for breast cancer, particularly in relation to high-dose
chemotherapy regimens. Nevertheless, these results could indicate that basal
apoptotic rates remain increased during long-term follow-up after antineoplastic
therapy for breast cancer.
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